Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe
Autoři:
Terhi T. Piltonen aff001; Maria Ruokojärvi aff001; Helle Karro aff002; Linda Kujanpää aff001; Laure Morin-Papunen aff001; Juha S. Tapanainen aff001; Elisabet Stener-Victorin aff004; Inger Sundrström-Poromaa aff005; Angelica L. Hirschberg aff006; Pernille Ravn aff007; Dorte Glintborg aff008; Jan Roar Mellembakken aff009; Thora Steingrimsdottir aff010; Melanie Gibson-Helm aff011; Eszter Vanky aff012; Marianne Andersen aff014; Riikka K. Arffman aff001; Helena Teede aff011; Kobra Falah-Hassani aff001
Působiště autorů:
Department of Obstetrics and Gynaecology, University of Oulu and Oulu University Hospital, Medical Research Centre, PEDEGO Research Unit, Oulu, Finland
aff001; Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Tartu, Tartu, Estonia
aff002; Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
aff003; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
aff004; Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden
aff005; Department of Women’s and Children’s Health, Karolinska Institutet and Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden
aff006; Department of Gynaecology and Obstetrics, Odense University Hospital, Odense, Denmark
aff007; Department of Endocrinology, Odense University Hospital, Odense, Denmark
aff008; Department of Reproductive Medicine, Division of Gynaecology and Obstetrics, Oslo University Hospital, Oslo, Norway
aff009; Department of Obstetrics and Gynecology, Landspitali University Hospital, School of Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland
aff010; Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
aff011; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
aff012; Department of Obstetrics and Gynecology, St Olav's Hospital, University Hospital of Trondheim, Trondheim, Norway
aff013; Department of Language and Culture, UiT—The Arctic University of Norway, Tromsø, Norway
aff014
Vyšlo v časopise:
PLoS ONE 14(12)
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pone.0226074
Souhrn
Objective
To date, little is known about differences in the knowledge, diagnosis making and treatment strategies of health care providers regarding polycystic ovary syndrome (PCOS) across different disciplines in countries with similar health care systems. To inform guideline translation, we aimed to study physician reported awareness, diagnosis and management of PCOS and to explore differences between medical disciplines in the Nordic countries and Estonia.
Methods
This cross-sectional survey was conducted among 382 endocrinologists and obstetrician-gynaecologists in the Nordic countries and Estonia in 2015–2016. Of the participating physicians, 43% resided in Finland, 18% in Denmark, 16% in Norway, 13% in Estonia, and 10% in Sweden or Iceland, and 75% were obstetrician-gynaecologists. Multivariable logistic regression models were run to identify health care provider characteristics for awareness, diagnosis and treatment of PCOS.
Results
Clinical features, lifestyle management and comorbidity were commonly recognized in women with PCOS, while impairment in psychosocial wellbeing was not well acknowledged. Over two-thirds of the physicians used the Rotterdam diagnostic criteria for PCOS. Medical endocrinologists more often recommended lifestyle management (OR = 3.6, CI 1.6–8.1) or metformin (OR = 5.0, CI 2.5–10.2), but less frequently OCP (OR = 0.5, CI 0.2–0.9) for non-fertility concerns than general obstetrician-gynaecologists. The physicians aged <35 years were 2.2 times (95% CI 1.1–4.3) more likely than older physicians to recommend lifestyle management for patients with PCOS for fertility concerns. Physicians aged 46–55 years were less likely to recommend oral contraceptive pills (OCP) for patients with PCOS than physicians aged >56 (adjusted odds ratio (OR) = 0.4, 95% CI 0.2–0.8).
Conclusion
Despite well-organized healthcare, awareness, diagnosis and management of PCOS is suboptimal, especially in relation to psychosocial comorbidities, among physicians in the Nordic countries and Estonia. Physicians need more education on PCOS and evidence-based information on Rotterdam diagnostic criteria, psychosocial features and treatment of PCOS, with the recently published international PCOS guideline well needed and welcomed.
Klíčová slova:
Psychological and psychosocial issues – Physicians – Endocrinology – Health education and awareness – Iceland – Polycystic ovary syndrome – Estonia – Reproductive endocrinology
Zdroje
1. McGowan MP. Polycystic ovary syndrome: a common endocrine disorder and risk factor for vascular disease. Curr Treat Options Cardiovasc Med. 2011;13:289–301. doi: 10.1007/s11936-011-0130-0 21562798
2. Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017;8:96351–8. doi: 10.18632/oncotarget.19180 29221211
3. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31:2841–55. doi: 10.1093/humrep/dew218 27664216
4. Neven ACH, Laven J, Teede HJ, Boyle JA. A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Semin Reprod Med. 2018;36:5–12. doi: 10.1055/s-0038-1668085 30189445
5. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32:1075–91. doi: 10.1093/humrep/dex044 28333286
6. Karjula S, Morin-Papunen L, Auvinen J, Ruokonen A, Puukka K, Franks S, et al. Psychological Distress Is More Prevalent in Fertile Age and Premenopausal Women With PCOS Symptoms: 15-Year Follow-Up. J Clin Endocrinol Metab. 2017;102:1861–9. doi: 10.1210/jc.2016-3863 28323926
7. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347–63. doi: 10.1093/humupd/dmq001 20159883
8. Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril. 2017;107:1380–6 e1. https://www.fertstert.org/article/S0015-282(17)30344-8/addons. doi: 10.1016/j.fertnstert.2017.04.011 28483503
9. Teede H, Gibson-Helm M, Norman RJ, Boyle J. Polycystic ovary syndrome: perceptions and attitudes of women and primary health care physicians on features of PCOS and renaming the syndrome. J Clin Endocrinol Metab. 2014;99:E107–11. doi: 10.1210/jc.2013-2978 24178791
10. Gibson-Helm M, Dokras A, Karro H, Piltonen T, Teede HJ. Knowledge and Practices Regarding Polycystic Ovary Syndrome among Physicians in Europe, North America, and Internationally: An Online Questionnaire-Based Study. Semin Reprod Med. 2018;36:19–27. doi: 10.1055/s-0038-1667155 30189447
11. Holm S, Liss PE, Norheim OF. Access to health care in the Scandinavian countries: ethical aspects. Health Care Anal. 1999;7:321–30. doi: 10.1023/A:1009460010196 10787795
12. GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018;391:2236–71. doi: 10.1016/S0140-6736(18)30994-2 29893224
13. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017 Dec 16;390(10113):2627–2642. doi: 10.1016/S0140-6736(17)32129-3 29029897
14. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33:1602–18. doi: 10.1093/humrep/dey256 30052961
15. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire. Eur J Endocrinol. 2014;171:489–98. doi: 10.1530/EJE-14-0252 25049203
16. Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome. Melbourne, Australia: Monash University; 2018.
17. Shorakae S, Boyle J, Teede H. Polycystic ovary syndrome: a common hormonal condition with major metabolic sequelae that physicians should know about. Intern Med J. 2014;44:720–6. doi: 10.1111/imj.12495 24909750
18. Gilbert EW, Tay CT, Hiam DS, Teede HJ, Moran LJ. Comorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews. Clin Endocrinol (Oxf). 2018;89:683–99.
19. Shafti V, Shahbazi S. Comparing Sexual Function and Quality of Life in Polycystic Ovary Syndrome and Healthy Women. J Family Reprod Health. 2016;10:92–8. 27648099
20. Tay CT, Teede HJ, Hill B, Loxton D, Joham AE. Increased prevalence of eating disorders, low self-esteem, and psychological distress in women with polycystic ovary syndrome: a community-based cohort study. Fertil Steril. 2019;112(2):353–361. doi: 10.1016/j.fertnstert.2019.03.027 31056307
21. Lagana AS, Rossetti P, Sapia F, Chiofalo B, Buscema M, Valenti G, et al. Evidence-Based and Patient-Oriented Inositol Treatment in Polycystic Ovary Syndrome: Changing the Perspective of the Disease. Int J Endocrinol Metab. 2017;15:e43695. doi: 10.5812/ijem.43695 28835764
22. Lagana AS, Vitale SG, Noventa M, Vitagliano A. Current Management of Polycystic Ovary Syndrome: From Bench to Bedside. Int J Endocrinol. 2018;2018:7234543. doi: 10.1155/2018/7234543 30538744
Článok vyšiel v časopise
PLOS One
2019 Číslo 12
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
- Kombinace metamizol/paracetamol v léčbě pooperační bolesti u zákroků v rámci jednodenní chirurgie